Difference between revisions of "Team:ETH Zurich"

m (added titles and changed some links)
Line 21: Line 21:
 
<section id="start" class="step">
 
<section id="start" class="step">
 
     <div class="why">
 
     <div class="why">
−
        <!--<h1> WHY</h1>-->
+
    <h1> WHY</h1>
 
         <p>Cancer kills over 8 million people every year. That's the entire population of Switzerland!</p>
 
         <p>Cancer kills over 8 million people every year. That's the entire population of Switzerland!</p>
 
         <p>We need more specific therapies because current approaches result in many side-effects. That's why we invented CATE, the first all-in-one living cancer therapeutic with an  
 
         <p>We need more specific therapies because current approaches result in many side-effects. That's why we invented CATE, the first all-in-one living cancer therapeutic with an  
 
         integrated two-step safety mechanism.
 
         integrated two-step safety mechanism.
 
         <p>A living cure to a living disease!</p>
 
         <p>A living cure to a living disease!</p>
−
         <p><a href="/Team:ETH_Zurich/Background" class="more">Why</a></p>
+
         <p><a href="/Team:ETH_Zurich/Background" class="more">Background</a></p>
 
     </div>
 
     </div>
 
</section>
 
</section>
Line 37: Line 37:
 
     </figure>
 
     </figure>
 
     <div>
 
     <div>
−
         <!--<h1>Vision</h1>-->
+
         <h1>Vision</h1>
 
<br>
 
<br>
 
<br>
 
<br>
Line 44: Line 44:
 
         <p>CATE consists of the non-pathogenic bacterium <span class="bacterium">E. coli</span> Nissle that has the intrinsic ability to home preferentially in tumors. It features two  
 
         <p>CATE consists of the non-pathogenic bacterium <span class="bacterium">E. coli</span> Nissle that has the intrinsic ability to home preferentially in tumors. It features two  
 
           safety checkpoint mechanisms to ensure only tumor cells are damaged.</p>
 
           safety checkpoint mechanisms to ensure only tumor cells are damaged.</p>
−
        <p>We are engineering <span class="bacterium">E. coli</span> Nissle to carry a MRI contrast and a cytotoxic agent so it can deliver both components to tumor sites.</p>
+
         <p> <a href="/Team:ETH_Zurich/Description" class="more">Project Description</a></p>
−
         <p> <a href="/Team:ETH_Zurich/Description" class="more">Vision</a></p>
+
 
     </div>
 
     </div>
 
</section>
 
</section>
Line 68: Line 67:
  
 
<section id="third" class="step">
 
<section id="third" class="step">
−
     <!--<h1>Treatment</h1>--> 
+
     <h1>Treatment</h1>
 
     <div>
 
     <div>
 
         <p>CATE is administered intravenously, travels through the blood and colonizes tumors. If enough bacteria have accumulated in the tumor, they make themselves visible and  
 
         <p>CATE is administered intravenously, travels through the blood and colonizes tumors. If enough bacteria have accumulated in the tumor, they make themselves visible and  
 
       start preparing the cytotoxic payload.</p>  
 
       start preparing the cytotoxic payload.</p>  
−
         <p> After the doctor has imaged the colonized tumor site with MRI, the release of the cancer-killing payload is activated in the required area. </p>
+
         <p> A doctor can then control the site with an MRI and activate release of the cancer-killing payload. </p>
 
         <p><a href="/Team:ETH_Zurich/#" class="more">Treatment</a></p>
 
         <p><a href="/Team:ETH_Zurich/#" class="more">Treatment</a></p>
 
     </div>
 
     </div>
Line 102: Line 101:
  
 
<section>
 
<section>
−
     <!--<h1>Engineering</h1>-->
+
     <h1>Engineering</h1>
 
     <div>
 
     <div>
 
         <p>We increased the understanding of the systems underlying mathematics by simulating the functions with models. The models were also used to define important questions to  
 
         <p>We increased the understanding of the systems underlying mathematics by simulating the functions with models. The models were also used to define important questions to  
Line 111: Line 110:
 
     <a href="/Team:ETH_Zurich/Applied_Design" class="more">Treatment</a>
 
     <a href="/Team:ETH_Zurich/Applied_Design" class="more">Treatment</a>
 
     -->
 
     -->
−
     <p><a href="/Team:ETH_Zurich/Engineering" class="more">Engineering</a></p>
+
     <p><a href="/Team:ETH_Zurich/Project_Design" class="more">Project Design</a></p>
 
</section>
 
</section>
  
Line 118: Line 117:
  
 
<section>
 
<section>
−
     <!--<h1>Achievements</h1>-->
+
     <h1>Achievements</h1>
 
     <div>
 
     <div>
 
         <p>We worked goal oriented and could experimentally confirm the predictions of the models. After testing every function individually, we combined them one after the other in milestone experiments to show the system in action. We created and characterized new BioBrick parts that are important for the iGEM competition and are freely for the future iGEM teams.</p>
 
         <p>We worked goal oriented and could experimentally confirm the predictions of the models. After testing every function individually, we combined them one after the other in milestone experiments to show the system in action. We created and characterized new BioBrick parts that are important for the iGEM competition and are freely for the future iGEM teams.</p>
Line 129: Line 128:
  
 
<section>
 
<section>
−
     <!--<h1>Human Practices</h1>-->
+
     <h1>Human Practices</h1>
 
     <div>
 
     <div>
 
         <p>We went beyond the lab and reached out to experts to better understand current technological and safety issues in order to enhance the design of our project. Further, we  introduced our project and the field of synthetic biology to the general public and together explored issues related to safety, ethics and sustainability.</p>
 
         <p>We went beyond the lab and reached out to experts to better understand current technological and safety issues in order to enhance the design of our project. Further, we  introduced our project and the field of synthetic biology to the general public and together explored issues related to safety, ethics and sustainability.</p>
Line 140: Line 139:
  
 
<section>
 
<section>
−
     <!--<h1>Team</h1>-->
+
     <h1>Team</h1>
 
     <div>
 
     <div>
 
         <p>We are an interdisciplinary team of eight master students of ETH Zürich who compete in the iGEM championship against hundreds of other teams from all over the world.</p>
 
         <p>We are an interdisciplinary team of eight master students of ETH Zürich who compete in the iGEM championship against hundreds of other teams from all over the world.</p>

Revision as of 16:22, 25 October 2017

WHY

Cancer kills over 8 million people every year. That's the entire population of Switzerland!

We need more specific therapies because current approaches result in many side-effects. That's why we invented CATE, the first all-in-one living cancer therapeutic with an integrated two-step safety mechanism.

A living cure to a living disease!

Background


Vision





CATE consists of the non-pathogenic bacterium E. coli Nissle that has the intrinsic ability to home preferentially in tumors. It features two safety checkpoint mechanisms to ensure only tumor cells are damaged.

Project Description














Treatment

CATE is administered intravenously, travels through the blood and colonizes tumors. If enough bacteria have accumulated in the tumor, they make themselves visible and start preparing the cytotoxic payload.

A doctor can then control the site with an MRI and activate release of the cancer-killing payload.

Treatment






To achieve all these novel functions, we designed a genetic circuit that is distributed over two de novo synthesized DNA molecules. All functions were tested and optimized to make the resulting circuit as safe and well characterized as possible.

Circuit



Engineering

We increased the understanding of the systems underlying mathematics by simulating the functions with models. The models were also used to define important questions to clarify in experiments.

Experimentally, we collected data to support and refine our models and to show that our system works.

Project Design



Achievements

We worked goal oriented and could experimentally confirm the predictions of the models. After testing every function individually, we combined them one after the other in milestone experiments to show the system in action. We created and characterized new BioBrick parts that are important for the iGEM competition and are freely for the future iGEM teams.

Achievements



Human Practices

We went beyond the lab and reached out to experts to better understand current technological and safety issues in order to enhance the design of our project. Further, we introduced our project and the field of synthetic biology to the general public and together explored issues related to safety, ethics and sustainability.

Human Practices



Team

We are an interdisciplinary team of eight master students of ETH Zürich who compete in the iGEM championship against hundreds of other teams from all over the world.

Team